New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs

Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors

(2017) Mona A. Abdullaziz et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors

(2017) Lin Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1 H -indazole-3-amine as multi-target RTKs inhibitors

(2017) Ying Sun et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4

(2017) Chuansheng Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Regulation of inflammation by members of the formyl-peptide receptor family

(2017) Keqiang Chen et al.   JOURNAL OF AUTOIMMUNITY

EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10 -ablation

(2017) Chao You et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines

(2017) Yanmin Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mechanistic insight into carnosol-mediated pharmacological effects: Recent trends and advancements

(2017) Dharambir Kashyap et al.   LIFE SCIENCES

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy

(2017) Biagio Ricciuti et al.   SEMINARS IN CANCER BIOLOGY

Angiogenesis in adenosquamous cancer of pancreas

(2017) Nicola Silvestris et al.   Oncotarget

The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells

(2017) Isabelle Corre et al.   Oncotarget

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents

(2017) Jinfeng Wang et al.   Scientific Reports

Dynamic Regulation of Vascular Permeability by Vascular Endothelial Cadherin-Mediated Endothelial Cell-Cell Junctions

(2017) Seung-Sik Rho et al.   JOURNAL OF NIPPON MEDICAL SCHOOL

Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply

(2017) Ken Liu et al.   Clinical and Translational Gastroenterology

Basic Fibroblast Growth Factor Induces Angiogenic Properties of Fibrocytes to Stimulate Vascular Formation during Wound Healing

(2016) Miho Nakamichi et al.   AMERICAN JOURNAL OF PATHOLOGY

EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease

(2016) Du Yang et al.   ANGIOGENESIS

Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells

(2016) Tae Young Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes

(2016) Jingya Zhang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting Angiogenesis in Colorectal Cancer

(2016) Sheetal Mehta Kircher et al.   CANCER JOURNAL

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia

(2016) L. Bachegowda et al.   CANCER RESEARCH

Shed proteoglycans in tumor stroma

(2016) Zoi Piperigkou et al.   CELL AND TISSUE RESEARCH

Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation

(2016) Wei Yan et al.   Chemical Biology & Drug Design

Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment

(2016) Ping-Pui Wong et al.   CURRENT BIOLOGY

Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions

(2016) Khurum Khan et al.   CURRENT DRUG TARGETS

Gut flora connects obesity with pathological angiogenesis in the eye

(2016) Rebecca Scholz et al.   EMBO Molecular Medicine

1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation

(2016) Sahar M. Abou-Seri et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation

(2016) Andrea Unzue et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions

(2016) Zhexuan Lin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer

(2016) JingHuan Lv et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Effects of a novel NADPH oxidase inhibitor (S42909) on wound healing in an experimental ischemic excisional skin model

(2016) Sandra Sotomayor et al.   EXPERIMENTAL DERMATOLOGY

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

(2016) Khalid Al Wadi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?

(2016) Georgios Oikonomopoulos et al.   Future Oncology

Role of thrombospondin 1 in liver diseases

(2016) Yanzhang Li et al.   HEPATOLOGY RESEARCH

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma

(2016) Sarah B. Whittle et al.   INVESTIGATIONAL NEW DRUGS

Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy

(2016) Margarida Capitão et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Lonicerae Japonicae Flos attenuates diabetic retinopathy by inhibiting retinal angiogenesis

(2016) Lingyu Zhou et al.   JOURNAL OF ETHNOPHARMACOLOGY

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis

(2016) Andrea Sartori et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel TIE-2 inhibitor BAY-826 displaysin vivoefficacy in experimental syngeneic murine glioma models

(2016) Hannah Schneider et al.   JOURNAL OF NEUROCHEMISTRY

Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants

(2016) J.-P. Meyer et al.   JOURNAL OF NUCLEAR MEDICINE

Targeting Angiogenesis in Cancer Treatments: Where do we Stand?

(2016) Nenad Petrovic   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

miRNA involvement in angiogenesis in age-related macular degeneration

(2016) Lei Wang et al.   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY

Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents

(2016) Chan Kyu Kim et al.   LEUKEMIA RESEARCH

Anti-vascular endothelial growth factor treatment induces blood flow recovery through vascular remodeling in high-fat diet induced diabetic mice

(2016) Lamei Xiao et al.   MICROVASCULAR RESEARCH

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro

(2016)   MOLECULES AND CELLS

Study of angiogenic signaling pathways in hemangioblastoma

(2016) Daniela Pierscianek et al.   NEUROPATHOLOGY

Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism

(2016) Minjian Zhao et al.   ONCOLOGY REPORTS

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

(2016) Beverly L. Falcon et al.   PHARMACOLOGY & THERAPEUTICS

Bioelectric impact of pathological angiogenesis on vascular function

(2016) Donald G. Puro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB

(2016) Cachétne S.X. Barrett et al.   PROSTATE

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

(2016) Domenico Ribatti et al.   Translational Oncology

Natural products against cancer angiogenesis

(2016) El Bairi Khalid et al.   TUMOR BIOLOGY

Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis

(2016) Ji Wang et al.   OncoTargets and Therapy

Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their Impact on Potency, Solubility, and hERG

(2016) Nello Mainolfi et al.   ACS Medicinal Chemistry Letters

Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign

(2016) Nello Mainolfi et al.   ACS Medicinal Chemistry Letters

Notch regulates BMP responsiveness and lateral branching in vessel networks via SMAD6

(2016) Kevin P. Mouillesseaux et al.   Nature Communications

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma

(2016) Maristella Bianconi et al.   Oncotarget

PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently

(2016) Lei Zheng et al.   Oncotarget

MicroRNA-206 attenuates the growth and angiogenesis in non-small cell lung cancer cells by blocking the 14-3-3ζ/STAT3/HIF-1α/VEGF signaling

(2016) Dong Xue et al.   Oncotarget

Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis

(2016) Jiang Jian et al.   Oncotarget

Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents

(2016) Marwa A. Aziz et al.   Scientific Reports

Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model

(2016) Shaunna L. Beedie et al.   Scientific Reports

CXCL9: evidence and contradictions for its role in tumor progression

(2016) Qiang Ding et al.   Cancer Medicine

Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats

(2016) Tzu-Hao Li et al.   PLoS One

Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer

(2016) Jing Chen et al.   Scientific Reports

Novel endogenous angiogenesis inhibitors and their therapeutic potential

(2015) Nithya Rao et al.   ACTA PHARMACOLOGICA SINICA

Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis

(2015) Srimathi Srinivasan et al.   ANGIOGENESIS

The pathogenic role of angiogenesis in rheumatoid arthritis

(2015) Hatem A. Elshabrawy et al.   ANGIOGENESIS

State of the art paper Platelet-derived growth factors induced lymphangiogenesis: evidence, unanswered questions and upcoming challenges

(2015) Andreea Adriana Jitariu et al.   Archives of Medical Science

LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways

(2015) Seung Woo Chung et al.   BIOMATERIALS

Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

(2015) Vera A. Machado et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

(2015) Wen Lu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: Exploration of diverse hinge-binding fragments

(2015) Ping Su et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Development of indazolylpyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers

(2015) Kristin Ebert et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies

(2015) Thomas K Chung et al.   CANCER BIOLOGY & THERAPY

Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model

(2015) Youya Nakazawa et al.   CANCER SCIENCE

Synthesis and Biological Evaluation of Novel Oxazolo[5,4-d]pyrimidines as Potent VEGFR-2 Inhibitors

(2015) Ya-Hui Deng et al.   CHEMISTRY & BIODIVERSITY

Aflibercept a new target therapy in cancer treatment: a review

(2015) Vincenzo Ricci et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance

(2015) Marco Rusnati et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Discovery of novel VEGFR-2 inhibitors. Part II: Biphenyl urea incorporated with salicylaldoxime

(2015) Hongping Gao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach

(2015) Yuanyuan Shan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model

(2015) Debanjan Bhattacharya et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling

(2015) Byung-Hak Kim et al.   EXPERIMENTAL DERMATOLOGY

The safety of regorafenib for the treatment of gastrointestinal stromal tumors

(2015) Piotr Rutkowski et al.   Expert Opinion On Drug Safety

A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort

(2015) Theresa L. Werner et al.   INVESTIGATIONAL NEW DRUGS

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

(2015) Erik L. Meredith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury

(2015) P. M. Abdul-Muneer et al.   MOLECULAR NEUROBIOLOGY

Role of EFNB2/EPHB4 signaling in spiral artery development during pregnancy: An appraisal

(2015) Hongmei Dong et al.   MOLECULAR REPRODUCTION AND DEVELOPMENT

Current status and future directions of anti-angiogenic therapy for gliomas

(2015) Wolfgang Wick et al.   NEURO-ONCOLOGY

Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy

(2015) R K Adapala et al.   ONCOGENE

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

(2015) Y. Zhao et al.   ONCOLOGIST

CXCL16 induces angiogenesis in autocrine signaling pathway involving hypoxia-inducible factor 1α in human umbilical vein endothelial cells

(2015) XIAOWEN YU et al.   ONCOLOGY REPORTS

Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth

(2015) Nella Prevete et al.   PHARMACOLOGICAL RESEARCH

Vasculopathy in scleroderma

(2015) Yoshihide Asano et al.   Seminars in Immunopathology

The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update

(2015) Liza C. Villaruz et al.   Current Oncology Reports

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy

(2015) Selwyn M. Prea et al.   Journal of Ophthalmology

Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation

(2015) Selma Rivas-Fuentes et al.   Journal of Cancer

Compensatory angiogenesis and tumor refractoriness

(2015) R N Gacche   Oncogenesis

The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression

(2015) Mi Sun Park et al.   Oncotarget

Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts

(2015) Mi Sun Park et al.   Oncotarget

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

(2014) Zheng Zhao et al.   ACS Chemical Biology

A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib

(2014) Subhajit Roy et al.   Anti-Cancer Agents in Medicinal Chemistry

In Vivo Imaging of Tumor Physiological, Metabolic, and Redox Changes in Response to the Anti-Angiogenic Agent Sunitinib: Longitudinal Assessment to Identify Transient Vascular Renormalization

(2014) Shingo Matsumoto et al.   ANTIOXIDANTS & REDOX SIGNALING

Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin

(2014) Brian Hutzen et al.   BMC CANCER

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

(2014) Klaus Mross et al.   BMC CANCER

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

(2014) Qiaoling Sun et al.   CANCER BIOLOGY & THERAPY

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

(2014) Sariah Liu et al.   CANCER TREATMENT REVIEWS

Developmental and pathological angiogenesis in the central nervous system

(2014) Mario Vallon et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)

(2014) Zofia Bielecka et al.   Current Signal Transduction Therapy

Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors

(2014) Lei Shi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

In Silico Discovery of Potential VEGFR-2 Inhibitors from Natural Derivatives for Anti-Angiogenesis Therapy

(2014) Jing Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)

(2014) ANDREAS K.A. GAUMANN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors

(2014) R. S. K. Vijayan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of treatment on the global dynamics of delayed pathological angiogenesis models

(2014) Leonid Berezansky et al.   JOURNAL OF THEORETICAL BIOLOGY

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network

(2014) T.V. Shiva Shankar et al.   VASCULAR PHARMACOLOGY

Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases

(2014) Jing Dong et al.   ACS Medicinal Chemistry Letters

Regorafenib for Gastrointestinal Malignancies

(2013) Giuseppe Aprile et al.   BIODRUGS

Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics

(2013) Yuya Oguro et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of N -[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2- b ]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1 H -pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor

(2013) Naoki Miyamoto et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: Design, synthesis and biological evaluation

(2013) Chen Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Anti-angiogenesis in cancer therapy: Hercules and hydra

(2013) S. Bellou et al.   CANCER LETTERS

Targeting angiopoietin-2 signaling in cancer therapy

(2013) Zeynep Eroglu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors

(2013) Yi-Hui Peng et al.   JOURNAL OF MEDICINAL CHEMISTRY

CXCL4L1–fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis

(2013) A.C. Prats et al.   MICROVASCULAR RESEARCH

Spatial regulation of VEGF receptor endocytosis in angiogenesis

(2013) Masanori Nakayama et al.   NATURE CELL BIOLOGY

Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth

(2013) Xiaojuan Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease

(2013) S. Goel et al.   Cold Spring Harbor Perspectives in Medicine

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

(2012) Farbod Shojaei   CANCER LETTERS

Development and strategies of VEGFR-2/KDR inhibitors

(2012) Lingyi Huang et al.   Future Medicinal Chemistry

Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography

(2012) Karine Lafleur et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the EphB4 Receptor for Cancer Diagnosis and Therapy Monitoring

(2012) Dan Li et al.   MOLECULAR PHARMACEUTICS

Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics

(2012) Hongtao Zhao et al.   ACS Medicinal Chemistry Letters

Developmental and Pathological Angiogenesis

(2011) Alicia S. Chung et al.   Annual Review of Cell and Developmental Biology

2-Methoxycinnamaldehyde inhibits tumor angiogenesis by suppressing Tie2 activation

(2011) Daishi Yamakawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series

(2011) Bernard Barlaam et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy

(2011) Yasufumi Sato   CANCER SCIENCE

Combined 3D-QSAR and Docking Modelling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors

(2011) Yuanxin Tian et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

(2011) Timothy P. Burkholder et al.   INVESTIGATIONAL NEW DRUGS

Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent

(2011) Robert L. Hudkins et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Molecular control of endothelial cell behaviour during blood vessel morphogenesis

(2011) Shane P. Herbert et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

(2011) Annette K. Larsen et al.   PHARMACOLOGY & THERAPEUTICS

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

(2010) Georg Martiny-Baron et al.   ANGIOGENESIS

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796

(2010) Justin Dietrich et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors

(2010) Catherine Bardelle et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents

(2010) Jie Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

(2010) Yingdi Wang et al.   NATURE

Discovery of novel taspine derivatives as antiangiogenic agents

(2009) Jie Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-Based Optimization of Potent and Selective Inhibitors of the Tyrosine Kinase Erythropoietin Producing Human Hepatocellular Carcinoma Receptor B4 (EphB4)

(2009) Karine Lafleur et al.   JOURNAL OF MEDICINAL CHEMISTRY

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacophore and docking-based combined in-silico study of KDR inhibitors

(2009) F.A. Pasha et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines

(2008) Catherine Bardelle et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines

(2008) Catherine Bardelle et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase

(2008) Victor J. Cee et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2

(2008) Qing-Qing Xie et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING